Abbott (ABT) October option implied volatility into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT)
October 16, 2024 4:18 PM EDTTD Cowen analyst Joshua Jennings reiterated a Buy rating and $130.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "ABT Posted Another Good Quarter: Third-quarter revenue of $10.64B and EPS of $1.21 exceeded Street forecasts of $10.55B and $1.20. Sales increased 4.9% on a reported basis and were up 7.6% on an organic basis including Covid test sales of $265M, which... More
JPMorgan Reiterates Overweight Rating on Abbott Labs (ABT)
October 16, 2024 4:12 PM EDTJPMorgan analyst Robbie Marcus reiterated an Overweight rating and $135.00 price target on Abbott Labs (NYSE: ABT)
The analyst comments "We like the setup for Abbott going forwards into 2025+ the quarter wasnt perfect, but we saw a strong Devices print and Covid testing upside offset 1x channel destocking in OUS... More
Abbott Labs (ABT) PT Raised to $125 at Jefferies
October 16, 2024 4:04 PM EDTJefferies analyst Matthew Taylor raised the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $120.00) while maintaining a Hold rating.
The analyst comments "ABT reported 3Q24 sales of $10.6B vs. cons. $10.55B, driven by MedTech outperformance/COVID tests, partially offset by softness in... More
Abbott Labs (ABT) PT Raised to $130 at Stifel
October 16, 2024 3:21 PM EDTStifel analyst Rick Wise raised the price target on Abbott Labs (NYSE: ABT) to $130.00 (from $125.00) while maintaining a Buy rating.
The analyst comments "Bottom Line: As 2025 approaches, during today's earnings call, Abbott management encouragingly suggested that the company is well-positioned for more-of-the-same high-singledigit revenue... More
Abbott Labs (ABT) PT Raised to $128 at Evercore ISI
October 16, 2024 2:42 PM EDTEvercore ISI analyst Vijay Kumar raised the price target on Abbott Labs (NYSE: ABT) to $128.00 (from $124.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: ABTs overall organic (ex COVID) of 8.2% was below recent trends (1H org grew ~10%), mostly due to one off issues in International Nutrition & Core Lab within Dx. On the Nutrition side, ABT lost some share in a specific geography and as a result took down channel inventory. On Dx side, China VBP (was expected) finally went into effect in 3Q along with price... More
